RankAlpha logo
Back to Rankings

LGND

LigandD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
LGND vs peer average
43/100
LGND vs. peer average (D vs. D)
Grade spread
A 1 · B 1 · C 2 · D 2 · F 3
Graded peers loaded
Coverage
9 graded
90% of tracked

Peer overview

RPRX is the first available peer comparator.

Royalty Pharma remains the clearest public model peer for diversified biopharma royalty cash-flow valuation, even though it operates at much larger scale.

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerRPRXRoyalty
LGND
Ligand
RPRX
Royalty
Grade
D
D
Momentum
35
63
Value
60
63
Sentiment
34
39
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Open Side-by-Side ComparisonCompare all

Grade position vs RPRX

LGND / RPRX
Grade Position
Below peers
LGND vs. peer average (D vs. D)
43/100
Momentum
35
RPRX
Value
60
RPRX
Sentiment
34
RPRX

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs LGND
1
RPRX
RPRX
D
40/100
Even
2
XOMA
XOMA
-
-
-
3
STVN
Stevanato Group SpA Common
C
60/100
-1
4
AMRX
Amneal Pharmaceuticals Inc Class A Common
A
100/100
-3
5
TVTX
Travere Therapeutics Inc Common
F
20/100
+1
RPRX is the first peer returned for this comparison set.